pre-IPO PHARMA

COMPANY OVERVIEW

Strand Therapeutics is an early-stage biotechnology company genetically programming revolutionary therapies to improve the lives of patients. Through pioneering work developed at MIT, Strand is building the world’s first smart mRNA therapeutics. Strand is expanding their innovative and rapidly expanding team that understands the value of working at a startup. Strand Therapeutics is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Immunology

  • WEBSITE

    https://www.strandtx.com


    CAREER WEBSITE

    https://www.strandtx.com/#careers


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments anri playground-ventures


    PRESS RELEASES


    Apr 24, 2023

    Strand Therapeutics Appoints Colleen Wilson as Chief People Officer


    Apr 17, 2023

    Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023


    Mar 14, 2023

    Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting


    Mar 1, 2023

    Strand Therapeutics Appoints Jay Stella as Chief Business Officer


    Nov 28, 2022

    Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million


    For More Press Releases


    Google Analytics Alternative